Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug 6;18(8):1717.
doi: 10.3390/ijms18081717.

Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection

Silvia Vandini  1 , Carlotta Biagi  2 , Marcello Lanari  3
Affiliations
Review

Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection

Silvia Vandini et al. Int J Mol Sci. .

Abstract

Respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae family, Orthopneumovirus genus. It is the leading cause of acute bronchiolitis and one of the most common causes of infant viral death worldwide, with infection typically occurring as recurrent seasonal epidemics. There are two major RSV subtypes, A and B, and multiple genotypes, which can coexist during RSV epidemic season every year and result in different disease severity. Recently, new RSV genomic sequences and analysis of RSV genotypes have provided important data for understanding RSV pathogenesis. Novel RSV strains do spread rapidly and widely, and a knowledge of viral strain-specific phenotypes may be important in order to include the more virulent strains in future therapeutical options and vaccine development. Here we summarize recent literature exploring genetic and molecular aspects related to RSV infection, their impact on the clinical course of the disease and their potential utility in the development of safe and effective preventive and therapeutic strategies.

Keywords: bronchiolitis; children; genotype; lower respiratory tract infections; monoclonal antibodies; respiratory syncytial virus; vaccines.

PubMed Disclaimer

Conflict of interest statement

All authors declare they have no conflicts of interest.

References

    1. Nair H., Nokes D.J., Gessner B.D., Dherani M., Madhi S.A., Singleton R.J., O’Brien K.L., Roca A., Wright P.F., Bruce N., et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis. Lancet. 2010;375:1545–1555. doi: 10.1016/S0140-6736(10)60206-1. - DOI - PMC - PubMed
    1. Anderson E.J., Carbonell-Estrany X., Blanken M., Lanari M., Sheridan-Pereira M., Rodgers-Gray B., Fullarton J., Rouffiac E., Vo P., Notario G., et al. Burden of severe respiratory syncytial virus disease among 33–35 weeks’ gestational age infants born during multiple respiratory syncytial virus seasons. Pediatr. Infect. Dis. J. 2017;36:160–167. doi: 10.1097/INF.0000000000001377. - DOI - PMC - PubMed
    1. Iwane M.K., Farnon E.C., Gerber S.I. Importance of global surveillance for respiratory syncytial virus. J. Infect. Dis. 2013;208:S165–S166. doi: 10.1093/infdis/jit484. - DOI - PubMed
    1. Sigurs N., Aljassim F., Kjellman B., Robinson P.D., Sigurbergsson F., Bjarnason R., Gustafsson P.M. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax. 2010;65:1045–1052. doi: 10.1136/thx.2009.121582. - DOI - PubMed
    1. Hall C.B., Weinberg G.A., Blumkin A.K., Edwards K.M., Staat M.A., Schultz A.F., Poehling K.A., Szilagyi P.G., Griffin M.R., Williams J.V., et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. J. Pediatr. 2013;132:e341–e348. doi: 10.1542/peds.2013-0303. - DOI - PubMed

MeSH terms